SMTL ID : 5x02.1

Crystal structure of the FLT3 kinase domain bound to the inhibitor FF-10101

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.40 Å

Oligo State

monomer

Ligands

1 x F6M: N-[(2S)-1-[5-[2-[(4-cyanophenyl)amino]-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxidanylidene-propan-2-yl]-4-(dimethylamino)-N-methyl-but-2-enamide(Covalent)

F6M.1: 17 residues within 4Å: Chain A: L.56, V.64, A.82, K.84, V.115, F.131, E.132, Y.133, C.134, C.135, Y.136, G.137, L.207, H.210, C.217, D.218, F.219 16 PLIP interactions: 16 interactions with chain A Hydrophobic interactions: A:L.56, A:V.64, A:V.64, A:A.82, A:V.115, A:F.131, A:Y.136, A:L.207, A:L.207, A:F.219, A:F.219 Hydrogen bonds: A:L.56, A:K.84, A:E.132, A:C.134, A:C.135

3 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 5 residues within 4Å: Chain A: R.144, R.147, G.274, V.275, N.276 4 PLIP interactions: 4 interactions with chain A Hydrogen bonds: A:G.274, A:N.276 Salt bridges: A:R.144, A:R.147 SO4.3: 3 residues within 4Å: Chain A: R.144, N.230, N.276 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:N.230, A:N.276 Salt bridges: A:R.144 SO4.4: 7 residues within 4Å: Chain A: E.44, F.45, R.47, C.121, T.122, L.123, S.124 8 PLIP interactions: 8 interactions with chain A Hydrogen bonds: A:E.44, A:E.44, A:R.47, A:T.122, A:L.123, A:S.124, A:S.124 Salt bridges: A:R.47

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Yamaura, T. et al., A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells withFLT3mutations. Blood (2018)

Release Date

2018-01-24

Peptides

Receptor-type tyrosine-protein kinase FLT3: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Receptor-type tyrosine-protein kinase FLT3